What if we could test spinal cord injury therapies in human tissue without a clinical trial?
It could be possible, as spinal cord organoids derived from human stem cells now replicate real injury responses.
Read more.
Organoids developed from human stem cells modeled spinal cord injuries, providing a powerful in vitro tool to evaluate regenerative therapies for CNS injuries.
[Functional brain mapping] Mitsuhashi et al.: “Callosal stimulation showed effective connectivity to homologous cortical regions. Sum of callosal-to-cortex propagation latencies matched interhemispheric latency.” Open access.
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
“At that time, I had no professional experience in the videogame industry, and I didn’t even really have an artist portfolio, so I made one in a bit of a rush.” Nonetheless, this was enough to convince Saber, and Hatté joined the team as an environment artist, working primarily on Tomb Raider 4–6 Remastered.
“My role on the team was specifically to work on the environments and remaster the textures,” Hatté says. “It was a life changing experience. I’m incredibly grateful to have been given that opportunity.”
Reamsters aside, Tomb Raider has been dormant since 2018’s Shadow of the Tomb Raider. But late last year, two new Lara Croft adventures were revealed—a second remake of the original game, and a new adventure by Crystal Dynamics pitched as a sequel to Tomb Raider: Underworld.
Extremely cool paper describing optically programmable ~0.3 mm robots with onboard computation and autonomous locomotion! These tiny rectangular machines carry solar cells, optical receivers, electrokinetic actuators, and more. As demonstrations, the authors programmed them (i) to report local temperature by doing a coded dance and (ii) swim towards warmth before stopping and rotating upon reaching a location with a certain level of heat. This is amazing and I hope such devices are further improved so they can be used in biological applications! Love it!
(https://www.science.org/doi/10.1126/scirobotics.adu8009)
Autonomous submillimeter robots are built with onboard sensing, computation, memory, communication, and locomotion.
Factors that promote inflammation in C9ORF72 mutation carriers with amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) have remained elusive. McCourt et al. identified pro-inflammatory forms of glycogen in gut contents of people with ALS/FTD and demonstrate that targeting glycogen in a C9orf72 mouse model extends lifespan and reduces neuroinflammation.
In this talk from the CSCSC 25 Conference on Complex Systems and Contemplative Studies, Dr. Michael Levin asks a question with deep resonance for both science and contemplative practice:
Researchers have identified a biological mechanism that helps explain why some lung and ovarian cancers become resistant to chemotherapy, offering insight into why cancers recur. The study, published in Nature Aging this month, investigated how platinum-based chemotherapies such as cisplatin negatively affect tumor behavior in non-small cell lung cancer (NSCLC) and high-grade serous ovarian cancer (HGSOC). Although these treatments are widely used, their long-term effectiveness is often limited when tumors return or stop responding.
Professor Ljiljana Fruk and Muhamad Hartono from the Department of Chemical Engineering and Biotechnology (CEB) contributed to the international collaboration, led by researchers from the Early Cancer Institute and the Cancer Research UK Cambridge Institute. Their involvement follows her Bionano Engineering group’s recent development of a urine test for early lung cancer detection.
In a study published today, Friday, February 13, 2026, in the journal Nature Aging, researchers show that blood-based biomarkers can support accurate dementia diagnosis across diverse populations when integrated with cognitive and neuroimaging measures. Blood-based biomarkers are emerging as one of the most promising advances for the global diagnosis of dementia, including Alzheimer’s disease and frontotemporal lobar degeneration. These tests offer a more accessible, scalable, and cost-effective alternative to traditional diagnostic tools such as brain imaging or cerebrospinal fluid analysis.
However, most blood-based biomarkers have been developed and validated primarily in relatively homogeneous populations. Genetic background, overall physical health, and environmental and social exposures can substantially influence biomarker levels, raising concerns about how well these tests perform across diverse populations worldwide.
